“朗齊生醫*（以下簡稱＂朗齊＂，股票代號：6876）赴瑞士日內瓦參加外交部舉辦的「2026年臺灣智慧醫療與健康產業展」，向國際展現朗齊新藥研發成果，並開拓更多國際合作契機。朗齊為本次參展臺灣企業中唯一的新藥公司，自主開發新成分新藥LXP103在治療肥胖與代謝疾病方面深具潛力，未來可望應用於體重管理、代謝疾病治療，並作為現有療法之輔助應用，提供差異化之開發方向，滿足全球體重管理領域未被滿足的市場需求。公司預計於年底前向美國FDA提出IND申請，以加速LXP103臨床開發進程，積極布局全球體重管理與代謝疾病市場。 外交部於5月17-19日第79屆世界衛生大會（WHA）期間，在全球領導者齊聚的瑞士日內瓦推出「臺灣智慧醫療與健康科技展」，邀集國內超過30家醫療院所、智慧醫療設備廠商及藥廠組成代表團，朗齊董事長王繼賢榮膺本次代表團副團長，參與此次日內瓦的重要國際活動，代表臺灣生醫產業展現在「智慧、創新、韌性醫療」三大核心主題下的世界級實力。 王繼賢董事長於開幕儀式上致詞表示，臺灣已建立起一個具備高度競爭力與活力的生醫產業生態系，結合世界級的研究機構與高效率的開發環境，讓創新能夠快速從研究端走向實際應用。朗齊生醫致力於推動創新藥物開發，兼顧科學嚴謹性與臨床實際價值，持續將前瞻研究轉化為具體可行的治療方案。目前朗齊主要藥物技術為LXP103以代謝機制重新定義體重管理議題。透過此次出訪，我們不僅希望向國際展現臺灣生醫的實力，更期待與全球夥伴建立連結，拓展合作機會，將臺灣的創新能量推向國際舞台。 朗齊總經理陳丘泓進一步介紹，自主開發的新成分新藥LXP103，具備新物質專利，並具有調節脂肪細胞代謝之潛力，具備安全性佳、半衰期長，以及藥物容易分布至周邊組織等特性。在肥胖實驗動物模式的大鼠試驗結果顯示，並展現長期體重控制效果；目前未觀察到明顯食慾抑制、發炎或毒性風險，相關數據進一步支持LXP103於肥胖與代謝疾病治療領域之開發潛力，並有望滿足體重管理領域尚未被滿足之醫療需求。 朗齊與國內權威科學家團隊合作，將進一步以全身減脂、對抗復胖等方向進行第二階段動物實驗，以確立後續適應症布局，未來LXP103可望應用於疾病治療及現有療法之輔助應用，展現其於體重管理領域的差異化優勢，預計年底前向美國FDA提出IND申請，以加速臨床試驗執行，並持續提升產品開發價值。 作為臺灣本土企業，朗齊匯集臺灣生技製藥人才進行藥物開發，透過與學術及研究機構的緊密合作，加速技術進展，展現創新與策略整合的能力。呼應「WHO Cares？ TAIWAN Cares！」的精神，朗齊致力於推動新型療法的研發，並始終秉持卓越的科學水平和臨床應用價值。朗齊核心項目LXP103，不僅體現了朗齊的科學實力，也展現了朗齊靈活調整研發策略以滿足不同臨床和市場需求的能力。從早期研究到策略定位，朗齊始終致力於實現創新與價值的最大化，藉由參與日內瓦的國際平台，將公司的研發成果推向全球舞台，並探索潛在的國際合作關係，將創新轉化為造福全球患者的有效療法
## **Longee Biopharm (6876) Heads to Taiwan Medical Exhibition in Geneva, Showcasing Innovation and Strategic Integration; LXP103 Offers Dual Regulation of Overall Weight Loss and Localized Fat Reduction with Significant Commercial Value (Stock Price on May 18: NT$19.9)**
Longee Biopharm (hereinafter referred to as “Longee”, stock code: 6876) has traveled to Geneva, Switzerland, to participate in the “2026 Taiwan Smart Medical and Health Technology Exhibition” organized by the Ministry of Foreign Affairs (MOFA). The company aims to showcase its novel drug R&D achievements to the international community and explore more opportunities for global collaboration.
As the only novel drug development company among the participating Taiwanese enterprises, Longee’s self-developed New Chemical Entity (NCE), **LXP103**, possesses significant potential in treating obesity and metabolic diseases. In the future, it is expected to be applied in weight management and metabolic disease treatments, as well as serving as an adjunctive therapy to existing treatments. This provides a differentiated development path to fulfill unmet market needs in the global weight management sector. The company expects to submit an Investigational New Drug (IND) application to the US FDA before the end of the year to accelerate the clinical development process of LXP103 and actively position itself in the global weight management and metabolic disease market.
During the 79th World Health Assembly (WHA) from May 17 to 19, MOFA launched the “Taiwan Smart Medical and Health Technology Exhibition” in Geneva, Switzerland, where global leaders gathered. A delegation comprising over 30 domestic medical institutions, smart medical equipment manufacturers, and pharmaceutical companies was invited. Dr. Chi-Hsien Wang, Chairman of Longee, was honored to serve as the deputy leader of the delegation. He participated in this significant international event in Geneva, representing Taiwan’s biomedical industry to demonstrate its world-class capabilities under the three core themes of “Smart, Innovative, and Resilient Healthcare.”
In his speech at the opening ceremony, Chairman Wang stated that Taiwan has established a highly competitive and vibrant biomedical industry ecosystem. By combining world-class research institutions with a highly efficient development environment, innovation can rapidly transition from the research stage to practical application. Longee Biopharm is committed to driving innovative drug development, balancing scientific rigor with clinical utility, and continuously transforming forward-looking research into tangible therapeutic solutions. Currently, Longee’s primary drug technology, LXP103, redefines weight management through metabolic mechanisms. “Through this visit, we not only hope to showcase the strength of Taiwan’s biomedical sector to the world but also look forward to establishing connections with global partners, expanding collaboration opportunities, and propelling Taiwan’s innovative energy onto the international stage,” Wang added.
Longee’s General Manager, Chen Chiu-hung, further introduced that the self-developed NCE drug LXP103 possesses composition of matter patents and has the potential to regulate adipocyte (fat cell) metabolism. It features excellent safety, a long half-life, and favorable drug distribution to peripheral tissues. Results from rat model studies in obesity experimental animal models demonstrated long-term weight control efficacy. Currently, no significant appetite suppression, inflammation, or toxicity risks have been observed. These data further support the development potential of LXP103 in the field of obesity and metabolic disease treatment, and it is expected to satisfy the unmet medical needs in the weight management arena.
Collaborating with a team of authoritative domestic scientists, Longee will conduct second-phase animal experiments focusing on systemic fat reduction and combating weight rebound to establish its subsequent indication pipeline. In the future, LXP103 is expected to be applied in disease treatment and as an adjunctive application to existing therapies, showcasing its differentiated advantages in the field of weight management. The company plans to submit an IND application to the US FDA before the end of the year to accelerate clinical trials and continuously enhance the product’s development value.
As a homegrown Taiwanese enterprise, Longee brings together Taiwan’s biotech and pharmaceutical talents for drug development. Through close collaboration with academic and research institutions, the company accelerates technological advancement, demonstrating its capacity for innovation and strategic integration. Echoing the spirit of **”WHO Cares? TAIWAN Cares!”**, Longee is dedicated to advancing the R&D of novel therapies while consistently upholding excellent scientific standards and clinical utility.
Longee’s core project, LXP103, not only embodies the company’s scientific prowess but also showcases its ability to flexibly adjust R&D strategies to meet diverse clinical and market demands. From early-stage research to strategic positioning, Longee has always been committed to maximizing innovation and value. By participating in this international platform in Geneva, the company aims to project its R&D achievements onto the global stage, explore potential international partnerships, and translate innovation into effective therapies that benefit patients worldwide.
